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PregnancySince the introduction of in vitro fertilization (IVF) in 1978, over ﬁve million babies have been
born worldwide using IVF. Contrary to the perception of many, IVF does not guarantee suc-
cess. Almost 50% of couples that start IVF will remain childless, even if they undergo multiple
IVF cycles. The decision to start or pursue with IVF is challenging due to the high cost, the bur-
den of the treatment, and the uncertain outcome. In optimal counseling on chances of a preg-
nancy with IVF, prediction models may play a role, since doctors are not able to correctly
predict pregnancy chances. There are three phases of prediction model development: model der-
ivation, model validation, and impact analysis. This review provides an overview on predictive
factors in IVF, the available prediction models in IVF and provides key principles that can be
used to critically appraise the literature on prediction models in IVF. We will address these
points by the three phases of model development.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Since the birth of Louise Brown in 1978, over ﬁve million ba-
bies have been born worldwide using in vitro fertilization (IVF)[1]. The number of in vitro fertilization cycles has increased
rapidly; in 2006, 458,759 cycles were reported in 32 European
countries, 99,199 cycles in the USA and 50,275 cycles in Aus-
tralia and New Zealand [2–4]. The number of cycles is increas-
ing each year even further.
The increase in IVF cycles is not caused by a sudden epi-
demic of infertility, but by increased access to IVF, and by
an expansion of the indications for IVF. Initially, IVF was per-
formed in couples with bilateral tubal occlusion [5]. In 1992,
intracytoplasmic sperm injection (ICSI) was ﬁrst introduced
and initiated in couples with severe male subfertility [6]. Later
on, IVF/ICSI was also applied in couples without an absolute
indication for IVF, such as unexplained subfertility, cervical
hostility, failed ovulation induction, endometriosis, or unilate-
ral tubal pathology [7,8]. The major difference between the ori-
ginal indication and the indications for which IVF is
296 L. van Loendersloot et al.conducted nowadays is that the couples with bilateral tubal
pathology or severe male subfertility have a zero chance of nat-
ural conception and completely depend on IVF/ICSI for a
pregnancy, while couples with the newer indications are sub-
fertile: they do have chances of natural conception, which
may or may not be better than with IVF.
Despite the lack of evidence that IVF is effective in couples
without an absolute IVF indication, IVF is often considered as
a last resort for all subfertile couples regardless of the etiology
of their subfertility [7–12]. Contrary to the perception of many,
IVF does not guarantee success; almost 38–49% of couples
that start IVF will remain childless, even if they undergo six
IVF cycles [13]. Subfertile couples should therefore be well in-
formed about the chances of success with IVF before starting
their ﬁrst or before continuing with a new IVF cycle. Based on
a couple’s speciﬁc probability, one should decide whether the
chances of success with IVF justify the burden, risks, and costs
of the treatment. The threshold at which probability to start or
to continue treatment may differ between different stakehold-
ers, such as insurance companies, the tax payer, and the
patients.
In optimal counseling on chances of a pregnancy after IVF,
pregnancy prediction models may play a role, since doctors are
not able to correctly predict pregnancy chances [14,15]. Predic-
tions made by clinicians on the basis of clinical experience or
‘‘gut-feeling’’ have only slight to fair reproducibility, indicating
that these predictions are likely to be inaccurate [15].
The efforts to develop prediction models for IVF reﬂect the
need for such models in clinical practice. This need can be ex-
plained by the inability of diagnostic tests to detect factors that
indicate subfertility with near 100% certainty in patients.
Accurate diagnostic tests would allow treatment to focus on
speciﬁc factors [16]. As IVF is currently used as an empirical
treatment and not as a causal intervention for a speciﬁc disor-
der, there is a strong need to distinguish between couples with
a good and a poor prognosis [16]. In the absence of random-
ized clinical trials, evaluating the effectiveness of IVF predic-
tion models can be used to counsel couples.
The development of a prediction model can be divided into
three phases: model derivation, model validation, and impact
analysis [16,17] (Fig. 1). In the model derivation phase, predic-
tors are identiﬁed, based on prior knowledge, and the weight
of each predictor (regression coefﬁcient) is calculated. In the
model validation phase, the performance of the model, i.e.
model’s ability to predict outcome is evaluated, and also the
‘‘generalizability’’ or ‘‘transportability’’ of the model is evalu-
ated. The third and ﬁnal phase consists of impact analysis. ThePhase 1: Model derivation
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Fig. 1 Three phases ofimpact analysis establishes whether the prediction model im-
proves doctors’ decisions by evaluating the effect on patient
outcome [16,17].
This review provides an overview on predictive factors in
IVF, the available prediction models in IVF and provides
key principles that can be used to critically appraise the litera-
ture on prediction models in IVF. We will address these points
by the three phases of model development: model derivation,
model validation, and impact analysis.
Phase 1: model derivation
Identiﬁcation of predictors
Candidate predictors are variables that are chosen to be stud-
ied for their predictive performance. These can include subject
demographics, clinical history, physical examination, disease
characteristics, test results, and previous treatments [18]. The
identiﬁcation of candidate predictors is preferably based on
subject knowledge, on pathophysiological mechanisms, or
the results of previous studies. Studied predictors should be
clearly deﬁned, standardized, and reproducible to enhance
generalizability and application of study results to practice
[18]. Researchers frequently measure more predictors than
can reasonably be analyzed. When the number of predictors
is much larger than the number of outcome events, there is a
risk of overestimating the predictive performance of the model.
To reduce the risk of false positive ﬁndings (predictors), at
least 10 individuals having (developed) the event of interest
are needed per candidate variable/predictor to allow for reli-
able prediction modeling [19].
A recent systematic review and meta-analysis on predictive
factors in IVF evaluated nine predictive factors: female age,
duration of subfertility, type of subfertility, indication for
IVF, basal follicle stimulating hormone (bFSH), fertilization
method, number of oocytes, number of embryos transferred,
and embryo quality [20].
Female age is one of the most important prediction factors
for success with IVF. Increasing female age was associated
with lower pregnancy chances in IVF (OR 0.95, 95% CI:
0.94–0.96) [20]. The decrease in fertility sets in after the age
of 30 years, with a marked decline after 35 years for both spon-
taneous as IVF-induced pregnancies [20–23]. The biological
explanation for the declining chances to conceive with increas-
ing female age most likely lies in the diminished ovarian re-
serve: the decrease in both quantity and quality of oocytes
[24]. Diminished ovarian reserve generally leads to a poor validation
ucible accuracy
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a successful pregnancy [25].
Increasing duration of subfertility is known to be associated
with a reduced possibility of natural conception [7,26–29] (ad-
justed hazard rate 0.83; 95% CI 0.78–0.88) [30]. In IVF, preg-
nancy rates were slightly lower in couples with a longer
duration of subfertility (OR 0.99, 95% CI: 0.98–1.00) [20],
even after adjustment for age [23,31–33].
Although the meta-analysis did not ﬁnd a signiﬁcant asso-
ciation between type of subfertility (primary versus secondary
subfertility) and pregnancy with IVF (unadjusted OR 1.04
95% CI: 0.65–1.43) [20], two recent, large studies did ﬁnd an
association. A previous ongoing pregnancy or live birth, ad-
justed for factors such as age, substantially increases the like-
lihood of success with IVF [31,33].
Through the years, several studies have reported on the asso-
ciation between the indication for IVF and pregnancy with IVF
without consistent results. These studies did not use the same
reference categories making the interpretation of the data difﬁ-
cult. There is evidence for an association between tubal pathol-
ogy and pregnancy with IVF. Women with tubal pathology
alone had lower pregnancy chances compared to women with
unexplained subfertility or other indications [23,31,34–36]. On
the other hand, another study suggested that women with tubal
pathology had higher pregnancy chances after IVF compared
with couples with unexplained subfertility, though not signiﬁ-
cantly [37]. There is also evidence for an association between
male subfertility and pregnancy with IVF. Although two studies
(N= 2628 cycles) reported that couples with male subfertility
have lower pregnancy chances than those with unexplained sub-
fertility [34,35], a very large cohort study (N= 144,018 cycles)
showed that couples with only male subfertility had increased
pregnancy chances compared to couples with unexplained sub-
fertility [31]. Since these studies use different reference categories
and different number of categories, it is not possible to compare
these results optimally. For future studies and the development
for prediction models, it would be useful to report every indica-
tion for IVF as a separate variable instead of combining all indi-
cations into one factor, to be able to compare all studies [20].
Basal FSH is an indirect estimate of ovarian reserve. A
higher bFSH value was associated with lower pregnancy rates
after IVF (OR 0.94; 95% CI: 0.88–1.00) [20].
Increasing number of oocytes was associated with higher
pregnancy chances with IVF (OR 1.04, 95% CI: 1.02–1.07)
[20]. A recent large cohort study (N= 400,135) also showed a
strong relationship between the number of oocytes and live birth
rate with IVF. The association is not linear; the best chance of
live birth is associated with approximately 15 oocytes [38].
Although the meta-analysis did not ﬁnd a signiﬁcant associa-
tion between pregnancy chances with ICSI compared to IVF
(OR0.95, 95%CI: 0.79–1.14) [20], amore recent large cohort study
(N= 144,018 cycles) reportedhigher chanceswith ICSI compared
to IVF (OR 1.28, 95% CI: 1.25–1.31), even after adjusting for all
relevant factors (OR 1.27, 95% CI: 1.23–1.31) [31].
The number of embryos transferred and embryo quality
were associated with increased pregnancy chances [20].
Estimation of the regression coefﬁcient
After identifying all potential predictors, a multivariable mod-
el can be constructed by regression analysis (logistic regressionor proportional hazard analysis). To evaluate the quantitative
effect of each predictor, the weight of each predictor is calcu-
lated by estimating the corresponding regression coefﬁcient in
a linear model.
Currently, over 21 papers have reported on the develop-
ment and or validation of models for the prediction of preg-
nancy with IVF (Table 1) [23,31–37,39–54].
Phase 2: model validation
The second phase in the development of a prediction model is
the evaluation of the model performance, i.e. model validation.
The performance of the model can be evaluated by calculating
its discriminative capacity and the degree of calibration. Dis-
crimination relates to how well a model can distinguish between
patientswith andwithout the outcome, i.e. discriminate between
women who achieved pregnancy and those who did not. Dis-
criminative capacity can be expressed by the area under the re-
ceiver operating characteristic curve (AUC), also known as
the c-statistic. A model with a c-statistic of 0.5 has no discrimi-
native power at all, while 1.0 would reﬂect perfect discrimina-
tion. Calibration relates to the agreement between observed
outcomes and calculated probabilities, i.e. if we calculate a
30% probability of a pregnancy with IVF, the observed relative
frequency of pregnancy should be approximately 30 out of 100
women. Calibration can be assessed by the Hosmer and Leme-
show goodness-of-ﬁt test statistic. A Hosmer–Lemeshow statis-
tics with a p-value above 0.05 implies that there is no signiﬁcant
miscalibration. In addition, calibration can also be assessed by
comparing the average calculated probabilities with the actual
proportions in disjoint subgroups. The average calculated prob-
abilities and actual proportions in each group can be plotted in a
calibration plot. In case of perfect calibration, all points in a cal-
ibration plot are on the diagonal, the line of equality, and prob-
abilities correspond perfectly to the actual proportions.
The validation phase can be subdivided in internal valida-
tion (phase 2a) and external validation (phase 2b). With inter-
nal validation, the model’s ability to predict the outcome in the
group of patients in which it was developed is evaluated
(reproducibility). Internal validation should be seen as validat-
ing the modeling process [56]. Of the 21 papers reporting on
IVF prediction model development, only 11 are also internally
validated [23,31–35,37,40,45,49–51,53–55].
Before being able to use prediction models for clinical deci-
sion making, it is not enough to demonstrate a reasonable or
good performance after internal validation. Most models show
too optimistic results, even after corrections from interval val-
idation procedures. It is essential to conﬁrm that any devel-
oped model also predicts well in a ‘‘similar but different’’
population outside the development set, i.e. external validation
(generalizability). The more these populations differ from the
development study, the stronger the test of generalizability of
the model [57].
There are three different types of external validation, tem-
poral validation, geographical validation, and domain valida-
tion. In temporal validation, the model is validated on new
patients that are from the same center as the development
set, but in a different time period [57,58]. In geographical
external validation, the model is validated on new patients
from a different center as the development set [57,58]. In do-
main validation, the model is validated on new patients that
Table 1 Characteristics on prediction models for pregnancy after IVF and IVF-eSET.
Author (year) Inclusion of embryo characteristics IVF-eSET Outcome
Van Loendersloot et al. [33] Yes No Ongoing pregnancy
Nelson and Lawlor [31] No No Live birth
van Weert et al. [54] No No Ongoing pregnancy
Lintsen et al. [23] No No Ongoing pregnancy
Verberg et al. [55] Yes Yes Ongoing pregnancy
Carrera-Rotllan et al. [40] No No Pregnancy
Ottosen et al. [35] Yes Yes Pregnancy
Ferlitsch et al. [42] No No Pregnancy
Hunault et al. [37] Yes Yes Ongoing pregnancy
Stolwijk et al. [52] No No Ongoing pregnancy
Bancsi et al. [34] No No Ongoing pregnancy
Minaretzis et al. [47] Yes No Live birth
Commenges-Ducos et al. [41] Globel model: No No Ongoing pregnancy
Model for implantation: Yes
Templeton et al. [32] No No Live birth
Stolwijk et al. [50] Model A: No No Ongoing pregnancy
Model B: Yes
Model C: Yes
Bouckaert et al. [39] Yes No Pregnancy
Haan et al. [43] No No Ongoing pregnancy
Hughes et al. [44] No No Ongoing pregnancy
Nayudu et al. [48] No No Ongoing pregnancy
298 L. van Loendersloot et al.are very different from the patients from which the model was
developed [57].
Of the 12 IVF models that went through internal valida-
tion, only four models have also been validated externally
[32,33,37,45,49,51,53]. One model was validated temporally,
the model calibrated well both in the development set and in
a separate validation set [33]. Three models have been vali-
dated geographically [32,37,45,49–51,53], but only one model
showed good calibration after validation [37,45]. So at this mo-
ment, there is only one model that is generalizable to other
clinics [37,45]. All other models have to be geographically val-
idated ﬁrst before using the models in practice.
A prediction model often performs less well in a new group
of patients than in the study group in which it was developed.
This can be caused by differences in the case-mix between the
development and validation population or by true differences
between populations [58]. Instead of simply rejecting the pre-
diction model and develop or ﬁt a new one, a better alternative
is to update existing prediction models and adjust or recali-
brate it to the local circumstances or setting of the validation
set [57,58]. As a result, the updated model is adjusted to the
characteristics of new individuals. Several methods for updat-
ing prediction models are possible. Most often, differences are
seen in the outcome frequency between the development and
new validation set. This results in poor calibration of the mod-
el; predicted probabilities are systematically too high or too
low. By adjusting the intercept (baseline risk) of the original
model, calibration can be improved. Additional updating
methods vary from adjustment of all predictor regression coef-
ﬁcients, adjustment of regression coefﬁcients for particular
predictor weight, to the addition of a completely new predictor
or marker to the existing model [57,58].
As patient populations may shift during the years, the
group of patients used for the development and validation of
the prediction model may differ from the current patient pop-
ulation. Reproductive techniques may evolve during the years,
new biomarkers with predictive value may become available,and the prediction model should be regularly updated and
adapted to the new setting, so that predictions for future pa-
tients remain valid and may even improve [58]. IVF centers
should therefore consider collecting their own data in elec-
tronic databases, so that with accumulation of the number of
IVF cycles over time, they can update the model with their
own data.
Phase 3: impact analysis
The third and ﬁnal phase in the evaluation of models is impact
analysis; it establishes whether the prediction model improves
decisions, in terms of quality or cost-effectiveness of patient
care [17,57,58]. This can be evaluated in one setting (phase
3a) or in varied settings (phase 3b). Different study designs
to evaluate the impact of a prediction model are possible, such
as comparing the outcomes between patients randomly as-
signed to receive management guided by the prediction model
and patients managed without the prediction model (care-as-
usual). A less valid alternative is to ask fertility specialists to
document therapeutic management decisions before and after
being ‘‘exposed’’ to a model’s predictions. None of the existing
IVF prediction models has reached the impact analysis phase
yet.Discussion
As IVF can be stressful physically and emotionally and is not
without health risks, subfertile couples should thus be well in-
formed about the chances for success with IVF before each cy-
cle. Unfortunately at this point, there are no randomized
controlled clinical trials comparing IVF with natural concep-
tion. Thus, the only way to counsel couples properly is by
model-based prognosis.
Over 21 articles have reported on the development and/or
validation of prediction models in IVF. Of these 21 articles,
Prediction models in in vitro fertilization; where are we? A mini review 299only two models had a good performance after external valida-
tion. Impact analyses have not yet been performed for any of
these models. Future research should focus more on updating
existing prediction models and adjust or recalibrate them to
the local circumstances or setting rather than developing new
prediction models. This way prediction models may strengthen
evidence-based, individualized decision-making and can con-
tribute to a rational use of scarce resources.
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